207 related articles for article (PubMed ID: 20838345)
21. The metabolic syndrome and schizophrenia.
Meyer JM; Stahl SM
Acta Psychiatr Scand; 2009 Jan; 119(1):4-14. PubMed ID: 19133915
[TBL] [Abstract][Full Text] [Related]
22. Schizophrenia, antipsychotics and metabolic disease.
Reynolds GP
J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
[No Abstract] [Full Text] [Related]
23. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
24. Metabolic syndrome: epidemiology and consequences.
Sacks FM
J Clin Psychiatry; 2004; 65 Suppl 18():3-12. PubMed ID: 15600380
[TBL] [Abstract][Full Text] [Related]
25. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
26. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
27. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.
Newcomer JW
J Clin Psychiatry; 2009; 70 Suppl 3():30-6. PubMed ID: 19570499
[TBL] [Abstract][Full Text] [Related]
28. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.
Mulder H; Franke B; van der-Beek van der AA; Arends J; Wilmink FW; Scheffer H; Egberts AC
J Clin Psychopharmacol; 2007 Aug; 27(4):338-43. PubMed ID: 17632216
[TBL] [Abstract][Full Text] [Related]
29. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
Van Gaal LF
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
[TBL] [Abstract][Full Text] [Related]
30. [The cardiovascular risk of schizophrenic patients].
Birkhofer A; Alger P; Schmid G; Förstl H
Neuropsychiatr; 2007; 21(4):261-6. PubMed ID: 18082107
[TBL] [Abstract][Full Text] [Related]
31. Tolerability of antipsychotics: recent controversies and future management.
Fleischhacker WW
J Clin Psychiatry; 2009 Mar; 70(3):e06. PubMed ID: 19317956
[TBL] [Abstract][Full Text] [Related]
32. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
[TBL] [Abstract][Full Text] [Related]
33. Metabolic syndrome and cardiovascular disease.
Citrome L
J Psychopharmacol; 2005 Nov; 19(6 Suppl):84-93. PubMed ID: 16280341
[TBL] [Abstract][Full Text] [Related]
34. Management of schizophrenia with medical disorders: cardiovascular, pulmonary, and gastrointestinal.
Short DD; Hawley JM; McCarthy MF
Psychiatr Clin North Am; 2009 Dec; 32(4):759-73. PubMed ID: 19944882
[TBL] [Abstract][Full Text] [Related]
35. Psychofarmacology in the prevention of somatic comorbid diseases in mentally ill patients.
Jukić V; Petrović Z; Brecić P; Krizaj A; Savić A; Baceković A; Bilić P; Susac J; Mandić A; Prazen I
Psychiatr Danub; 2009 Sep; 21(3):350-5. PubMed ID: 19794355
[TBL] [Abstract][Full Text] [Related]
36. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
37. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
38. Effects of atypical antipsychotics on weight and serum lipid levels.
Meyer JM
J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
[TBL] [Abstract][Full Text] [Related]
39. Schizophrenia, the metabolic syndrome and diabetes.
Holt RI; Peveler RC; Byrne CD
Diabet Med; 2004 Jun; 21(6):515-23. PubMed ID: 15154933
[TBL] [Abstract][Full Text] [Related]
40. [Time for every psychiatric clinic to take full responsibility for metabolic side effects of antipsychotic drugs!].
Gothefors D; Jarbin H
Lakartidningen; 2010 Mar 24-30; 107(12):845-6. PubMed ID: 20432835
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
